Midostaurin

133 interactions 1 explained in plain English 326 cited references
Also sold as: Rydapt Rydapt®
About Midostaurin

Midostaurin is used with other chemotherapy drugs to treat certain types of acute myeloid leukemia (AML; a type of cancer of the white blood cells). Midostaurin is also used to certain types of mastocytosis (a blood disorder in which there are too many mast cells [a certain kind of white blood cell]). Midostaurin is in… Read the full Midostaurin drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Major

Midostaurin Nefazodone Increased midostaurin exposure Details Midostaurin Nelfinavir Viracept Increased midostaurin exposure Details Midostaurin Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Midostaurin Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Midostaurin Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Midostaurin Ozanimod Increased BCRP substrate exposure Details Midostaurin Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Midostaurin Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Midostaurin Phenytoin Dilantin Decreased midostaurin exposure Details Midostaurin Pitavastatin Livalo Increased OATP1B1 substrate exposure Details Midostaurin Posaconazole Noxafil Increased posaconazole exposure and increased midostaurin exposure Details Midostaurin Pravastatin Pravachol Increased OATP1B1 substrate exposure Details Midostaurin Ranolazine Aspruzyo Increased ranolazine exposure and an increased CYP3A4 substrate exposure Details Midostaurin Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Midostaurin Repaglinide Prandin® Increased OATP1B1 substrate exposure Details Midostaurin Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Midostaurin Revefenacin Yupelri Increased OATP1B1 substrate exposure Details Midostaurin Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Midostaurin Rifampin Rifadin Decreased midostaurin exposure Details Midostaurin Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Midostaurin Ritonavir Norvir Increased midostaurin exposure Details Midostaurin Rosuvastatin Crestor Increased BCRP and OATP1B1 substrate exposure Details Midostaurin Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Saquinavir Increased midostaurin exposure Details Midostaurin Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Midostaurin Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Midostaurin Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Midostaurin St John's Wort Decreased midostaurin exposure Details Midostaurin Sulfasalazine Azulfidine Increased BCRP substrate exposure Details Midostaurin Suzetrigine Journavx Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Midostaurin Taurursodiol Decreased exposure of the CYP3A4 substrate Details Midostaurin Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Midostaurin Telaprevir Increased midostaurin exposure Details Midostaurin Telithromycin Increased midostaurin exposure Details Midostaurin Tenofovir Alafenamide Increased tenofovir alafenamide exposure Details Midostaurin Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Midostaurin Topotecan Hycamtin Increased BCRP substrate exposure Details Midostaurin Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Midostaurin Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Midostaurin Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.